Chennai, Feb. 25 -- CURO Biosciences Private Limited plans to launch its saliva-based cancer detection products in April, following the successful completion of clinical trials, said a top company official.
"The company has completed its large-scale clinical trial on 1,000 patients. The multi-centre clinical study was conducted across leading cancer care institutions, including HCG Nagpur, Ranchi, Bangalore, and the Regional Cancer Hospital (Rashtrasant Tukdoji Cancer Hospital, Nagpur), a Government of India-recognised centre of excellence," said Shubhendra Singh Thakur, CEO.
Thakur said the US Food and Drug Administration (USFDA) recently granted the Breakthrough Device Designation to the company's product, ErlySign, a saliva-based oral ...